WO2023108126 - COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION
National phase entry:
Publication Number
WO/2023/108126
Publication Date
15.06.2023
International Application No.
PCT/US2022/081277
International Filing Date
09.12.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION
[French]
COMPOSITIONS ET PROCÉDÉS D'ADMINISTRATION ORALE
Applicants **
IMAGINE PHARMA LLC
Inventors
THAI, Ngoc
POLLETT, Jonathan
Priority Data
63/288,579
11.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4125 | |
| EPO | Filing, Examination, Granting | 56567 | |
| Japan | Filing, Examination, Granting | 3898 | |
| South Korea | Filing, Examination, Granting | 5569 | |
| USA | Filing, Examination, Granting | 20910 |
Total:
91,069
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Compositions and methods for the targeted delivery of therapeutic polypeptides and protein-based therapeutics across the gastrointestinal lining are disclosed. In one aspect, provided is a polypeptide construct comprising (a) a first polypeptide comprising an amino acid sequence that is at least 80% identical to an amino acid sequence selected from any one of SEQ ID NO: 1-40; and (b) a second polypeptide, wherein the second polypeptide is heterologous to the first polypeptide. In one aspect, the heterologous polypeptide is a therapeutic polypeptide.[French]
Des compositions et des procédés pour l'administration ciblée de polypeptides thérapeutiques et d'agents thérapeutiques à base de protéines à travers le revêtement gastro-intestinal sont divulgués. Dans un aspect, la divulgation concerne une construction polypeptidique comprenant (a) un premier polypeptide comprenant une séquence d'acides aminés qui est identique à au moins 80 % à une séquence d'acides aminés choisie parmi l'une quelconque de SEQ ID No : 1-40 ; et (b) un second polypeptide, le second polypeptide étant hétérologue au premier. Dans un aspect, le polypeptide hétérologue est un polypeptide thérapeutique.